174422-23-2Relevant articles and documents
Heterocyclic derivative and pharmaceutical composition comprising the same
-
Page/Page column 252, (2016/01/10)
The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun
Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist
Sime, Mairi,Allan, Amanda C.,Chapman, Paul,Fieldhouse, Charlotte,Giblin, Gerard M.P.,Healy, Mark P.,Lambert, Millard H.,Leesnitzer, Lisa M.,Lewis, Ann,Merrihew, Raymond V.,Rutter, Richard A.,Sasse, Rosemary,Shearer, Barry G.,Wilson, Timothy M.,Xu, Robert X.,Virley, David J.
scheme or table, p. 5568 - 5572 (2011/10/09)
The peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPARγ partial agonists has been identified. The optimization of PPARγ activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPARγ partial agonist, is described.
Synthesis and antioxidant capacities of some new benzimidazole derivatives
Ayhan-Kilcigil, Guelguen,Kus, Canan,Oezdamar, Elcin D.,Can-Eke, Benay,Ican, Muemtaz
, p. 607 - 611 (2008/12/21)
In this study, we prepared some new oxadiazolyl benzimidazole derivatives and investigated their antioxidant properties by determination of microsomal NADPH-dependent inhibition of lipid peroxidation levels (LP assay) and microsomal ethoxyresorufin O-deet